Hersey M, Mereu M, Jones C, Bartole M, Chen A, Cao J
Eur J Neurosci. 2024; 59(10):2436-2449.
PMID: 38444104
PMC: 11108740.
DOI: 10.1111/ejn.16293.
Hersey M, Bacon A, Bailey L, Lee M, Chen A, Leggio L
J Neurochem. 2022; 164(5):613-623.
PMID: 36420597
PMC: 10766115.
DOI: 10.1111/jnc.15730.
Tyagi P, Garg S, Tejan V, Dhillon M
Indian J Pharmacol. 2022; 54(2):148-149.
PMID: 35546468
PMC: 9249150.
DOI: 10.4103/ijp.ijp_868_21.
Mereu M, Hiranita T, Jordan C, Chun L, Lopez J, Coggiano M
Neuropsychopharmacology. 2020; 45(9):1518-1526.
PMID: 32340023
PMC: 7360549.
DOI: 10.1038/s41386-020-0680-5.
Febbraro S, Shea T, Cravo A
Clin Pharmacol Drug Dev. 2020; 9(4):486-495.
PMID: 32133778
PMC: 7318178.
DOI: 10.1002/cpdd.777.
Striatal histamine mechanism in the pathogenesis of restless legs syndrome.
Lai Y, Hsieh K, Cheng Y, Chew K, Nguyen D, Ramanathan L
Sleep. 2019; 43(2).
PMID: 31671173
PMC: 8491621.
DOI: 10.1093/sleep/zsz223.
Effect of systemically administered oxytocin on dose response for methylphenidate self-administration and mesolimbic dopamine levels.
Lee M, Rohn M, Zanettini C, Coggiano M, Leggio L, Tanda G
Ann N Y Acad Sci. 2019; 1455(1):173-184.
PMID: 31074517
PMC: 10014164.
DOI: 10.1111/nyas.14101.
Distinct effects of (R)-modafinil and its (R)- and (S)-fluoro-analogs on mesolimbic extracellular dopamine assessed by voltammetry and microdialysis in rats.
Keighron J, Giancola J, Shaffer R, DeMarco E, Coggiano M, Slack R
Eur J Neurosci. 2018; 50(3):2045-2053.
PMID: 30402972
PMC: 8294075.
DOI: 10.1111/ejn.14256.
Decrease of cocaine, but not heroin, self-administration and relapse by the tyrosine kinase inhibitor masitinib in male Sprague Dawley rats.
Belin-Rauscent A, Lacoste J, Hermine O, Moussy A, Everitt B, Belin D
Psychopharmacology (Berl). 2018; 235(5):1545-1556.
PMID: 29520592
PMC: 5920000.
DOI: 10.1007/s00213-018-4865-0.
Revisiting Antipsychotic-induced Akathisia: Current Issues and Prospective Challenges.
Salem H, Nagpal C, Pigott T, Teixeira A
Curr Neuropharmacol. 2016; 15(5):789-798.
PMID: 27928948
PMC: 5771055.
DOI: 10.2174/1570159X14666161208153644.
Lack of Specific Involvement of (+)-Naloxone and (+)-Naltrexone on the Reinforcing and Neurochemical Effects of Cocaine and Opioids.
Tanda G, Mereu M, Hiranita T, Quarterman J, Coggiano M, Katz J
Neuropsychopharmacology. 2016; 41(11):2772-81.
PMID: 27296151
PMC: 5026747.
DOI: 10.1038/npp.2016.91.
Preclinical studies on the reinforcing effects of cannabinoids. A tribute to the scientific research of Dr. Steve Goldberg.
Tanda G
Psychopharmacology (Berl). 2016; 233(10):1845-66.
PMID: 27026633
PMC: 5073892.
DOI: 10.1007/s00213-016-4244-7.
Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter.
Reith M, Blough B, Hong W, Jones K, Schmitt K, Baumann M
Drug Alcohol Depend. 2014; 147:1-19.
PMID: 25548026
PMC: 4297708.
DOI: 10.1016/j.drugalcdep.2014.12.005.
Preference for distinct functional conformations of the dopamine transporter alters the relationship between subjective effects of cocaine and stimulation of mesolimbic dopamine.
Kohut S, Hiranita T, Hong S, Ebbs A, Tronci V, Green J
Biol Psychiatry. 2014; 76(10):802-9.
PMID: 24853388
PMC: 4353924.
DOI: 10.1016/j.biopsych.2014.03.031.
Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist.
Desai R, Grandy D, Lupica C, Katz J
J Pharmacol Exp Ther. 2013; 348(1):106-15.
PMID: 24194528
PMC: 3868881.
DOI: 10.1124/jpet.113.208538.
The neurobiology of modafinil as an enhancer of cognitive performance and a potential treatment for substance use disorders.
Mereu M, Bonci A, Newman A, Tanda G
Psychopharmacology (Berl). 2013; 229(3):415-34.
PMID: 23934211
PMC: 3800148.
DOI: 10.1007/s00213-013-3232-4.
Relations between stimulation of mesolimbic dopamine and place conditioning in rats produced by cocaine or drugs that are tolerant to dopamine transporter conformational change.
Tanda G, Li S, Mereu M, Thomas A, Ebbs A, Chun L
Psychopharmacology (Berl). 2013; 229(2):307-21.
PMID: 23612854
PMC: 3758386.
DOI: 10.1007/s00213-013-3109-6.
Self-administration of cocaine induces dopamine-independent self-administration of sigma agonists.
Hiranita T, Mereu M, Soto P, Tanda G, Katz J
Neuropsychopharmacology. 2012; 38(4):605-15.
PMID: 23187725
PMC: 3572457.
DOI: 10.1038/npp.2012.224.
Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions.
Harmey D, Griffin P, Kenny P
Nicotine Tob Res. 2012; 14(11):1300-18.
PMID: 23024249
PMC: 3611986.
DOI: 10.1093/ntr/nts201.
Effects of the histamine H₁ receptor antagonist and benztropine analog diphenylpyraline on dopamine uptake, locomotion and reward.
Oleson E, Ferris M, Espana R, Harp J, Jones S
Eur J Pharmacol. 2012; 683(1-3):161-5.
PMID: 22445882
PMC: 3340496.
DOI: 10.1016/j.ejphar.2012.03.003.